Guide-line of the radio-iodine ( 131I) therapy in Graves' disease and thyroid cancer

Kakuigaku

Volumn 42, Issue 1, 2005, Pages 17-32

  Mori, Yutaka ^a   Kusakabe, Kiyoko ^b   Ikekubo, Katsuji ^c   Ishikawa, Naofumi ^d   Nakada, Kunihiro ^e   Kanaya, Shinichi ^b   Misaki, Takashi ^f   Yokoyama, Kunihiko ^g   Kubo, Atsushi ^h   Higashi, Tatsuya ⁱ   Itou, Kouichi ^d   Noguchi, Yasushi ^j   Tsuchimochi, Shinsaku ^k   Togawa, Takashi ^l  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^b TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

^c Hyogo Health Service Association   (Japan)

^d ITO HOSPITAL   (Japan)

^e HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^f TENRI HOSPITAL   (Japan)

^g KANAZAWA UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCE   (Japan)

^h KEIO UNIVERSITY   (Japan)

ⁱ KYOTO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^j Noguchi Hospital   (Japan)

^k KAGOSHIMA UNIVERSITY   (Japan)

^l CHIBA CANCER CENTER   (Japan)

more..

Author keywords

Graves' disease; Hyperthyroidism; Japanese guide line; Radio iodine therapy; Thyroid cancer

Indexed keywords

IODINE 131; LIOTHYRONINE; THYROTROPIN; THYROXINE; RADIOACTIVE IODINE; RADIOPHARMACEUTICAL AGENT;

ARTICLE; GRAVES DISEASE; HUMAN; HYPERTHYROIDISM; PRACTICE GUIDELINE; THYROID CANCER; THYROID TUMOR;

GRAVES DISEASE; HUMANS; IODINE RADIOISOTOPES; RADIOPHARMACEUTICALS; THYROID NEOPLASMS;

EID: 20144387037     PISSN: 00227854     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (13)

1. Herts S, Robert A: Application of radioactive iodine in the therapy of Graves' disease. J Clin Invest 1942; 21: 624.
2. Sanger EL, Thoma GE, Thompkins EA: Incidence of leukemia following treatment of hyperthyroidism. JAMA 1968; 205: 855-862.
3. Ron E, Doody MM, Becker DV, Brill AD, Curtis RE, Goldman MB, et al: Cancer mortality following treatment for adult hyperthyroidism. JAMA 1998; 280: 347-355.
4. Franklyn JA, Maisonneuve P, Sheppard M, Betteridge J, Boyle P: Cancer incidence and mortality after radioiodine treatment for hyperthyroidism: a population-based cohort study. Lancet 1991; 353: 2111-2115.
5. Mazzaferri EL, Jhiang SM: Long-term impact of initial surgical and medical therapy on papillary and follicular thyroid cancer. Am J Med 1994; 97: 418-428.
6. Mori T, Sugawa H, Kosugi S, Ueda M, Hai N, Matsuda A: Recent trends in the management of Graves' hyperthyroidism in Japan: Opinion survey results, especially on the combination therapy of antithyroid drug and thyroid hormone. Endocr J 1997; 44: 509-517.
7. Vanderlaan WP, Storrie VM: A survey of the factors controlling thyroid function, with especial reference to newer views on antithyroid substances. Pharmacol Rev 1995; 7: 301-334.
8. Jpn J Clin Pharmacol Ther 1986; 17: 271-272.
9. ICRP-32/186/00(Ver8).
10. Nagayama Y, Izumi M, Nagataki S: The management of hyperthyroidism due to Graves' disease in Japan in 1988. Endocr J 1989; 36: 299-314.